Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice

World Journal of Gastroenterology

Volumn 16, Issue 43, 2010, Pages 5416-5423

  Wang, Hui ^a   Liu, Bo ^a   Tian, Jia He ^a   Xu, Bai Xuan ^a   Guan, Zhi Wei ^a   Qu, Bao Lin ^a   Liu, Chang Bin ^a   Wang, Rui Min ^a   Chen, Ying Mao ^a   Zhang, Jin Ming ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Colorectal cancer; Irradiation; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; BETA3 INTEGRIN; FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 27; KI 67 ANTIGEN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; COLORECTAL CANCER; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MICRO POSITRON EMISSION TOMOGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION RESPONSE; WESTERN BLOTTING;

EID: 78649704845     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i43.5416     Document Type: Article

References (32)

1. Mathis KL, Nelson H, Pemberton JH, Haddock MG, Gunderson LL. Unresectable colorectal cancer can be cured with multimodality therapy. Ann Surg 2008; 248: 592-598
2. Mohiuddin M, Marks J, Marks G. Management of rectal cancer: shortvs long-course preoperative radiation. Int J Radiat Oncol Biol Phys 2008; 72: 636-643
3. Low G, Tho LM, Leen E, Wiebe E, Kakumanu S, McDonald AC, Poon FW. The role of imaging in the pre-operative staging and post-operative follow-up of rectal cancer. Surgeon 2008; 6: 222-231
4. Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, Schuster T, Meyer zum Büschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M, Dechow T. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007; 13: 3552-3558
5. Rajendran JG, Mankoff DA. Beyond detection: novel applications for PET imaging to guide cancer therapy. J Nucl Med 2007; 48: 855-856
6. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005; 65: 4202-4210
7. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van Gelder M, Windhorst AD, Slotman BJ, Lammertsma AA. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2'-[18F]fluoro-Dglucose (FDG) and 3'-[18F]fluoro-3'-deoxythymidine (FLT). Mol Imaging Biol 2007; 9: 340-347
8. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD, Haberkorn U. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDGand FLT-PET. Leuk Lymphoma 2007; 48: 746-753
9. Chao KS. 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esopha geal cancer. Semin Oncol 2007; 34: S31-S36.
10. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluoro-thymidine using preclinical tumor models. Clin Cancer Res 2006; 12: 4590-4597
11. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007; 24: 1172-1185
12. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, Lee SW, Cho KJ, Cheon GJ, Moon DH. Use of 3'-deoxy-3' -[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006; 33: 412-419
13. Liang L, Qu L, Ding Y. Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest 2007; 25: 427-434
14. Duranton B, Holl V, Schneider Y, Carnesecchi S, Gossé F, Raul F, Seiler N. Polyamine metabolism in primary human colon adenocarcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). Amino Acids 2003; 24: 63-72
15. Zhao L, Liu L, Wang S, Zhang YF, Yu L, Ding YQ. Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 2007; 133: 771-782
16. Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging 2005; 5: 51-57
17. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, Stroobants S, Penninckx F, Haustermans K. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG? Acta Oncol 2008; 47: 1237-1248
18. Okazumi S, Dimitrakopoulou-Strauss A, Schwarzbach MH, Strauss LG. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis. Hell J Nucl Med 2009; 12: 223-228
19. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11: 1112-1119
20. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, Kanaji N, Asakura M, Ohkawa M. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008; 35: 236-245
21. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, Kaji M, Haba R, Nishiyama Y. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2009; 36: 382-388
22. Yamamoto Y, Nishiyama Y, Ishikawa S, Gotoh M, Bandoh S, Kanaji N, Asakura M, Ohkawa M. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr 2008; 32: 432-437
23. Been LB, Suurmeijer AJ, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31: 1659-1672
24. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van Gelder M, Windhorst AD, Slotman BJ, Lammertsma AA. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2'-deoxy-2' -[18F]fluoro-D-glucose (FDG) and 3'-[18F]fluoro-3'-de-oxythymidine (FLT). Mol Imaging Biol 2007; 9: 340-347
25. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, Lee SW, Cho KJ, Cheon GJ, Moon DH. Use of 3'-deoxy-3' -[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 2006; 33: 412-419
26. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, Hirano T, Kohno E, Tsukada H. Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 2004; 45: 1754-1758
27. Murayama C, Harada N, Kakiuchi T, Fukumoto D, Kamijo A, Kawaguchi AT, Tsukada H. Evaluation of D-18F-FMT, 18F-FDG, L-11C-MET, and 18F-FLT for monitoring the response of tumors to radiotherapy in mice. J Nucl Med 2009; 50: 290-295
28. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49 Suppl 2: 64S-80S.
29. Robertson JH, Iga AM, Sales KM, Winslet MC, Seifalian AM. Integrins: a method of early intervention in the treatment of colorectal liver metastases. Curr Pharm Des 2008; 14: 296-305
30. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y, Ohkawa M. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1610-1616
31. Kushlinsky NE, Trapeznikova MF, Gershtein ES, Glibin PA, Kazantceva IA, Kilichbekov MB. Vascular endothelial growth factor and its type 2 receptor in tumors and serum of patients with renal cancer. Bull Exp Biol Med 2008; 145: 744-747
32. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103